

# CITATION REPORT

List of articles citing

**KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab**

**DOI: 10.1093/annonc/mdm496**  
**Annals of Oncology, 2008, 19, 508-15.**

**Source:** <https://exaly.com/paper-pdf/44250446/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
687	The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologics in the treatment of metastatic colorectal cancer. <b>2007</b> , 21, 1089-108		31
686	[Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology]. <b>2008</b> , 29, 93-6		6
685	[Molecular targets for colon cancer. VEGF, EGFR - and what else?]. <b>2008</b> , 29 Suppl 2, 200-3		2
684	[Molecular pathologic KRAS mutation analysis. A prerequisite of effective antibody treatment for metastasized colorectal cancer]. <b>2008</b> , 79, 576-9		8
683	Can we predict the response to epidermal growth factor receptor targeted therapy?. <b>2008</b> , 3, 87-99		1
682	The role of biologics in stomach cancer. <b>2008</b> , 3, 71-79		2
681	Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era. <b>2008</b> , 3, 223-225		
680	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. <b>2008</b> , 1, 101-108		
679	The role of targeted therapy in the treatment of advanced colorectal cancer. <b>2008</b> , 9, 357-74		5
678	Molecular predictors of response to EGFR antibodies in colorectal cancer. <b>2008</b> , 4, 119-125		
677	Predictive markers of cetuximab efficacy in metastatic colorectal cancer. <b>2008</b> , 4, 184-192		
676	Individualization of therapy based on clinical and molecular parameters. <b>2008</b> , 4, 193-200		1
675	EGFR and colon cancer: a clinical view. <i>Clinical and Translational Oncology</i> , <b>2008</b> , 10, 6-13	3.6	47
674	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. <b>2008</b> , 453, 417-31		241
673	The biological properties of cetuximab. <b>2008</b> , 68, 93-106		96
672	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <b>2008</b> , 54, e11-79		451
671	Targeted therapy of cancer: new roles for pathologists in colorectal cancer. <b>2008</b> , 21 Suppl 2, S23-30		41

670	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. <b>2008</b> , 99, 83-9	155
669	Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. <b>2008</b> , 99, 551-2	35
668	Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. <b>2008</b> , 99, 1729-34	38
667	Faits marquants du 3e Congrès francophone de chirurgie digestive et hépatobiliaire. <b>2008</b> , 145, 4S1-4S12	
666	Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. <b>2008</b> , 28, 18S-22S	27
665	[Non-resectable metastases from colorectal cancers]. <b>2008</b> , 32, S140-4	
664	K-ras mutations and benefit from cetuximab in advanced colorectal cancer. <b>2008</b> , 359, 1757-65	2912
663	Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. <b>2008</b> , 7, 184-90	129
662	Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer. <b>2008</b> , 7, 300-8	6
661	Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. <b>2008</b> , 7 Suppl 2, S52-7	13
660	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. <b>2008</b> , 6, 86-90	2
659	Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. <b>2008</b> , 263, 170-81	106
658	Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer. <b>2008</b> , 28, 269-81	35
657	First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent. <b>2008</b> , 34 Suppl 2, S3-7	73
656	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. <b>2008</b> , 9, 962-72	623
655	Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008. <b>2008</b> , 7, 233-9	
654	Predictive Markers in Colorectal Cancer. <b>2008</b> , 19, 231-238	
653	Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck. <b>2008</b> , 22, 1193-208, ix	5

652	KRAS mutations: an old oncogene becomes a new predictive biomarker. <b>2008</b> , 10, 493-5		41
651	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. <b>2008</b> , 14, 5869-76		154
650	Optimal approach to potentially resectable liver metastases from colorectal cancer. <b>2008</b> , 8, 1533-9		4
649	The role of molecular markers in predicting response to therapy in patients with colorectal cancer. <i>Molecular Diagnosis and Therapy</i> , <b>2008</b> , 12, 87-98	4.5	18
648	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <b>2008</b> , 26, 5705-12		1358
647	Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1288-1292	10.3	95
646	Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?. <b>2008</b> , 8, 1471-80		11
645	KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. <b>2008</b> , 26, 2228-30; author reply 2230-1		26
644	The effects of common genetic variants in oncogenes on ovarian cancer survival. <b>2008</b> , 14, 5833-9		30
643	K-Ras mutation status as a predictive biomarker in metastatic colorectal cancer. <b>2008</b> , 2, 97-9		2
642	In Reply. <b>2008</b> , 26, 2601-2602		3
641	Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. <i>Annals of Oncology</i> , <b>2008</b> , 19, 1442-1449	10.3	40
640	High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. <b>2008</b> , 13, 1270-5		197
639	Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. <b>2008</b> , 14, 7884-95		102
638	2) Chemical and Molecular-targeted Therapy of Digestive System Neoplasm. <b>2008</b> , 97, 2098-2104		
637	KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancer. <b>2008</b> , 5, 365-365		
636	The clinical management of hepatic neoplasms. 1-24		1
635	Chirurgische Arbeitsgemeinschaft Onkologie (CAO-V) der Deutschen Gesellschaft ff. Viszeralchirurgie. <b>2008</b> , 31, 138-140		

634	Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer. <b>2009</b> , 1, CMT.S2039		1
633	[Biological criteria of eligibility for a treatment against EGFR]. <b>2009</b> , 25 Spec No 1, 21-4		0
632	[Chemotherapy for colorectal cancer]. <b>2009</b> , 54, 355-63		2
631	Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. <b>2009</b> , 4, e7746		68
630	The marriage of growth factor inhibitors and chemotherapy: bliss or bust?. <b>2009</b> , 27, 1545-8		8
629	COLD-PCR finds hot application in mutation analysis. <b>2009</b> , 55, 2077-8		18
628	Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <b>2009</b> , 1, 167-81		6
627	mAbs: a business perspective. <b>2009</b> , 1, 179-84		73
626	KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. <b>2009</b> , 27, 158-9; author reply 159		12
625	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , <b>2009</b> , 20, 84-90	10.3	327
624	TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. <b>2009</b> , 100, 1330-5		75
623	Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. <b>2009</b> , 14, 29-39		60
622	Mutations and response to epidermal growth factor receptor inhibitors. <b>2009</b> , 15, 1133-9		107
621	Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. <b>2009</b> , 66, 2105-12		22
620	Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). <i>Annals of Oncology</i> , <b>2009</b> , 20, 1375-82 <sup>10.3</sup>	10.3	61
619	Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. <i>Annals of Oncology</i> , <b>2009</b> , 20, 985-92	10.3	268
618	Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. <b>2009</b> , 27, 1822-8		95
617	PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. <b>2009</b> , 15, 3184-8		276

616	The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. <b>2009</b> , 14, 22-8	189
615	Impact of Fc{gamma}RIIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. <b>2009</b> , 27, 1122-9	425
614	Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. <b>2009</b> , 27, 2751-7	86
613	Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies. <b>2009</b> , 4, 46-50	
612	Clinical pharmacology, biomarkers and personalized medicine: education please. <b>2009</b> , 3, 685-700	8
611	K-ras mutations and cetuximab in colorectal cancer. <b>2009</b> , 360, 833-4; author reply 835-6	21
610	Setting future standards for KRAS testing in colorectal cancer. <b>2009</b> , 10, 1-3	16
609	KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. <b>2009</b> , 9, 565-77	8
608	Prognostic signature for pancreatic cancer: are we close?. <b>2009</b> , 5, 313-21	12
607	New trends in epidermal growth factor receptor-directed monoclonal antibodies. <b>2009</b> , 1, 965-82	10
606	K-RAS mutation in the screening, prognosis and treatment of cancer. <b>2009</b> , 3, 757-69	31
605	The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2009</b> , 20, 879-84	10.3 65
604	Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. <i>Annals of Oncology</i> , <b>2009</b> , 20, 469-74	10.3 73
603	EGFR-targeted therapies in lung cancer: predictors of response and toxicity. <b>2009</b> , 10, 59-68	54
602	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. <b>2009</b> , 15, 7322-9	159
601	Can epidermal growth factor receptor-fluorescent in situ hybridization predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer?. <b>2009</b> , 27, 464-5; author reply 465-7	5
600	Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. <b>2009</b> , 18, 62-71	44
599	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. <i>Annals of Oncology</i> , <b>2009</b> , 20, 213-26	10.3 31

598	ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer. <b>2009</b> , 5, 71-2		19
597	A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. <b>2009</b> , 9, 145		23
596	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <b>2009</b> , 9, 303		60
595	Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. <b>2009</b> , 9, 347		36
594	ERBBs in the gastrointestinal tract: recent progress and new perspectives. <b>2009</b> , 315, 583-601		37
593	High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. <b>2010</b> , 14, 2122-31		68
592	Novel multiple, monoallelic KRAS mutations at codon 12 and 13. <b>2009</b> , 125, 2744-5		4
591	Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. <b>2009</b> , 115, 3609-17		58
590	The role of salvage treatment in advanced colorectal cancer. <b>2009</b> , 71, 53-61		11
589	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 737-747	3.6	7
588	Molecular predictors of response to EGFR antibodies in colorectal cancer. <b>2009</b> , 5, 57-63		1
587	The importance of KRAS status in managing metastatic colorectal cancer. <b>2009</b> , 5, 129-134		
586	Incidence of KRAS status in ongoing adjuvant trials in colon cancer. <b>2009</b> , 5, 171-178		2
585	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. <b>2009</b> , 4, 311-22		3
584	Cancer colorectal mEaostatique et thEapies ciblEs. <b>2009</b> , 3, 230-238		
583	Molecular targeted treatment and radiation therapy for rectal cancer. <b>2009</b> , 185, 371-8		48
582	Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. <b>2009</b> , 158, 1-9		221
581	Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. <b>2009</b> , 22, 1023-31		102

580	Genetics: Predictive value of KRAS mutations in chemoresistant CRC. <b>2009</b> , 6, 306-7	26
579	Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. <b>2009</b> , 28 Suppl 1, S38-45	25
578	Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. <b>2009</b> , 100, 1087-94	103
577	Epidermal growth factor receptor inhibitors: current status and future directions. <b>2009</b> , 33, 245-94	9
576	Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. <b>2009</b> , 101, 1182-92	104
575	Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. <b>2009</b> , 15, 91-100	52
574	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. <b>2009</b> , 360, 563-72	1089
573	Pharmacogenomics and -genetics in colorectal cancer. <b>2009</b> , 61, 375-80	14
572	Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. <b>2009</b> , 27, 663-71	1360
571	American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. <b>2009</b> , 27, 2091-6	1008
570	Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. <b>2009</b> , 15, 4508-13	83
569	Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. <b>2009</b> , 35, 262-71	157
568	Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. <b>2009</b> , 45, 1117-1128	71
567	Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?. <b>2009</b> , 45, 2768-81	61
566	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <b>2009</b> , 6, 519-27	341
565	Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <b>2009</b> , 360, 1408-17	3065
564	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. <b>2009</b> , 27, 5068-74	284
563	Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <b>2009</b> , 101, 998-1004	73

562	Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. <b>2009</b> , 8, 15-21		16
561	KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. <b>2009</b> , 8, 135-40		3
560	Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. <b>2009</b> , 2, 18		35
559	Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. <b>2009</b> , 62, 886-91		40
558	Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology. <b>2009</b> , 11, 381-9		8
557	A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. <b>2009</b> , 11, 543-52		92
556	Chemotherapy for lung cancer: the state of the art in 2009. <b>2009</b> , 9, 1365-78		36
555	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. <b>2009</b> , 27, 2622-9		368
554	Treatment of patients with colorectal cancer: emphasis on liver metastases. <b>2009</b> , 10, 109-24		1
553	Clinical biomarkers in oncology: focus on colorectal cancer. <i>Molecular Diagnosis and Therapy</i> , <b>2009</b> , 13, 103-14	4-5	37
552	KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. <b>2009</b> , 27, 1130-6		188
551	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. <b>2009</b> , 101, 1308-24		424
550	Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. <b>2009</b> , 3, 5-9		12
549	How to integrate biologicals in the continuum of care. <b>2009</b> , 45 Suppl 1, 57-69		
548	Impact of molecular markers on treatment selection in advanced colorectal cancer. <b>2009</b> , 45 Suppl 1, 70-8		8
547	Beyond the KRAS test. <b>2009</b> , 45 Suppl 1, 398-9		3
546	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. <b>2009</b> , 27, 5924-30		586
545	KRAS mutation testing in colorectal cancer. <b>2009</b> , 16, 196-203		82

544	KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. <b>2009</b> , 15, 110-3	26	
543	Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. <b>2009</b> , 6, 145-157	2	
542	KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. <b>2009</b> , 16, 554-61	22	
541	Chemotherapy for the elderly patient with colorectal cancer. <b>2010</b> , 16, 241-52	17	
540	Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. <b>2010</b> , 16, 226-34	5	
539	Is it prime time for personalized medicine in cancer treatment?. <b>2010</b> , 7, 387-397	1	
538	Novel agents in the treatment of metastatic colorectal cancer. <b>2010</b> , 16, 273-82	6	
537	KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. <b>2010</b> , 17, 1168-76	86	
536	Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. <b>2010</b> , 17, 624-33	48	
535	KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. <b>2010</b> , 17, 1429-34	96	
534	Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung. <b>2010</b> , 3, 87-93		
533	Epidermal growth factor receptor (EGFR) mRNA levels and protein expression levels in primary colorectal cancer and corresponding liver metastases. <b>2010</b> , 65, 825-31	13	
532	[Molecular diagnostics in lung carcinoma for therapy stratification]. <b>2010</b> , 31, 22-8	3	
531	Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. <b>2010</b> , 25, 713-21	22	
530	Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom. <b>2010</b> , 16, 779-788	1	
529	MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. <b>2010</b> , 27, 1066-72	12	
528	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. <i>Clinical and Translational Oncology</i> , <b>2010</b> , 12, 533-42	3.6	48
527	The Biology of K-Ras and B-Raf Mutations in Colorectal Cancer. <b>2010</b> , 6, 206-211		

526	Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. <b>2010</b> , 28, 353-60	22
525	Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. <b>2010</b> , 10, 136	44
524	Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. <b>2010</b> , 10, 189	58
523	Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. <b>2010</b> , 10, 340	56
522	KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. <b>2010</b> , 10, 660	57
521	Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancer. <b>2010</b> , 10, 681	15
520	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. <b>2010</b> , 32, 437-53	140
519	Therapeutic modulation of k-ras signaling in colorectal cancer. <b>2010</b> , 15, 502-16	27
518	Mechanisms of resistance to HER family targeting antibodies. <b>2010</b> , 316, 1083-100	123
517	The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. <b>2010</b> , 117, 358-65	46
516	Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. <b>2010</b> , 49, 1024-34	157
515	Implications of key trials in advanced nonsmall cell lung cancer. <b>2010</b> , 116, 1155-64	13
514	Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. <b>2010</b> , 127, 1321-31	41
513	Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <b>2010</b> , 127, 1941-7	56
512	Integration of panitumumab into the treatment of colorectal cancer. <b>2010</b> , 74, 16-26	20
511	Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. <b>2010</b> , 78, 472-8	49
510	Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. <b>2010</b> , 6, 286-91	7
509	Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection. <b>2010</b> , 91, 500-5	30

508	Oncogenic mutations as predictive factors in colorectal cancer. <b>2010</b> , 29, 3033-43		87
507	Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. <b>2010</b> , 102, 1137-44		21
506	Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. <b>2010</b> , 103, 1765-72		61
505	Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. <b>2010</b> , 2010, 392652		24
504	Analysis of KRAS Mutations of Exon 2 Codons 12 and 13 by SNaPshot Analysis in Comparison to Common DNA Sequencing. <b>2010</b> , 2010, 789363		21
503	KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. <i>Current Oncology</i> , <b>2010</b> , 17 Suppl 1, S31-40	2.8	47
502	Chemotherapy for Colorectal Cancer. <b>2010</b> , 53, 582		3
501	A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. <b>2010</b> , 15, 699-731		121
500	Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. <b>2010</b> , 16, 2709-14		27
499	New strategies for treatment of KRAS mutant metastatic colorectal cancer. <b>2010</b> , 16, 2921-6		64
498	Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. <b>2010</b> , 16, 304-10		56
497	Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. <b>2010</b> , 16, 2205-13		89
496	Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS. <b>2010</b> , 40, 699-701		2
495	The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. <b>2010</b> , 15, 73-84		38
494	Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. <b>2010</b> , 251, 254-60		68
493	Advances in target therapy for lung cancer. <b>2010</b> , 40, 101-6		58
492	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <b>2010</b> , 28, 4706-13		789
491	Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. <b>2010</b> , 15, 157-67		27

490	Understanding resistance to EGFR inhibitors-impact on future treatment strategies. <b>2010</b> , 7, 493-507		503
489	EGF receptor in lung cancer: a successful story of targeted therapy. <b>2010</b> , 10, 1577-87		12
488	Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. <b>2010</b> , 10, 499-505		16
487	New and potential clinical applications of KRAS as a cancer biomarker. <b>2010</b> , 4, 383-95		5
486	Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening. <b>2010</b> , 285, 18838-46		38
485	Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1579-1584	10.3	50
484	Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 6, vi1-10	10.3	35
483	Incorporating new data on colorectal cancer into nursing practice. <b>2010</b> , 14, 92-100		4
482	Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch?. <b>2010</b> , 28, 3207-10		28
481	Predictive genomic biomarkers. <b>2012</b> , 355, 173-88		1
480	Application of a pharmacogenetic test adoption model to six oncology biomarkers. <b>2010</b> , 7, 441-450		19
479	Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. <b>2010</b> , 15, 390-404		135
478	Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. <b>2010</b> , 12, 443-52		32
477	Molecular Testing in Colorectal Carcinoma. <b>2010</b> , 3, 429-45		1
476	Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. <i>Molecular Cancer</i> , <b>2010</b> , 9, 75	42.1	167
475	Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. <b>2010</b> , 49, 729-40		53
474	KRAS mutation screening in colorectal cancer: From paper to practice. <b>2010</b> , 9, 22-30		16
473	Integrating biomarkers into clinical decision making for colorectal cancer. <b>2010</b> , 9 Suppl 1, S16-27		6

472	In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. <b>2010</b> , 138, 435-46	176
471	KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. <b>2010</b> , 12, 35-42	77
470	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. <b>2010</b> , 16, 790-9	369
469	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <b>2010</b> , 28, 4697-705	1405
468	Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. <b>2010</b> , 28, 1181-9	99
467	Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation. <b>2010</b> , 46, 869-79	42
466	Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. <b>2010</b> , 46, 2781-7	74
465	A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. <b>2010</b> , 12, 292-9	86
464	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. <b>2010</b> , 11, 38-47	738
463	Réhabilitation secondaire des métastases hépatiques initialement non résectables chez les patients porteurs d'un cancer colorectal : un véritable enjeu !. <b>2010</b> , 147, S40-S54	
462	Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. <b>2010</b> , 4, 535-41	12
461	ACB-PCR Quantification of K-RAS Codon 12 GAT and GTT Mutant Fraction in Colon Tumor and Non-Tumor Tissue. <b>2010</b> , 28, 364-375	36
460	EGFR and KRAS in colorectal cancer. <b>2010</b> , 51, 71-119	83
459	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1535-1546	10.3 572
458	Cetuximab in the treatment of patients with colorectal cancer. <b>2011</b> , 11, 937-49	38
457	Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. <b>2011</b> , 11, 1433-45	12
456	Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. <b>2011</b> , 29, 2011-9	1463
455	KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. <b>2011</b> , 135, 245-52	63

454	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. <b>2011</b> , 17, 4901-14	143
453	Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. <b>2011</b> , 13, 64-73	120
452	KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. <b>2011</b> , 13, 436-45	33
451	Immunohistology of the Gastrointestinal Tract. <b>2011</b> , 500-540	
450	Implementing prognostic and predictive biomarkers in CRC clinical trials. <b>2011</b> , 8, 222-32	104
449	Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. <b>2011</b> , 29, 1050-8	92
448	Lower Gastrointestinal Tract and Microsatellite Instability. <b>2011</b> , 423-433	
447	Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. <b>2011</b> , 204, 439-46	35
446	Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. <b>2011</b> , 47, 2673-80	
445	Laboratory methods for KRAS mutation analysis. <b>2011</b> , 11, 635-42	44
444	Impact of KRAS Mutations on Management of Colorectal Carcinoma. <b>2011</b> , 2011, 219309	15
443	EGFR Signaling in Colorectal Carcinoma. <b>2011</b> , 2011, 932932	81
442	Management of stage IV rectal cancer: palliative options. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 835-47	5.6 39
441	Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in 1 <sup>st</sup> line cetuximab-based therapy of colorectal cancer patients. <b>2011</b> , 6, e15980	101
440	Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. <b>2011</b> , 9, 13-25	28
439	Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. <b>2011</b> , 54, 1170-8	63
438	Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX. <b>2011</b> , 22 Suppl 2, S1-7	
437	Molecular predictors of response to chemotherapy in colorectal cancer. <b>2011</b> , 17, 114-26	31

436	Biomarkers in Colorectal Cancer. <b>2011</b> , 20, 26-31	
435	Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?. <b>2011</b> , 13, 542-8	3
434	Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. <b>2011</b> , 30, 561-74	105
433	Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. <b>2011</b> , 104, 488-95	84
432	EGFR-targeted therapy. <b>2011</b> , 317, 2765-71	83
431	Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. <b>2011</b> , 41, 1067-74	15
430	Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS. <b>2011</b> , 29, 688-93	11
429	A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). <b>2011</b> , 29, 1038-44	11
428	Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors. <b>2011</b> , 28, 427-35	40
427	KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. <b>2011</b> , 38, 1315-20	27
426	PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. <b>2011</b> , 38, 1347-51	12
425	BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. <b>2011</b> , 38, 2219-23	63
424	Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. <b>2011</b> , 137, 1379-96	24
423	Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. <b>2011</b> , 26, 823-33	49
422	Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports. <b>2011</b> , 26, 1241-8	28
421	Pathophysiologie und Molekular Diagnostik beim nichtkleinzelligen Lungenkarzinom. <b>2011</b> , 17, 670-678	
420	Konzept der prädiktiven Molekularpathologie. <b>2011</b> , 17, 437-452	1
419	[Molecular diagnostics of lung cancer for treatment stratification]. <b>2011</b> , 52, 146, 148-50, 152-4	3

4 <sup>18</sup>	Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. <b>2011</b> , 67, 153-63	34
4 <sup>17</sup>	Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. <b>2011</b> , 28, 1048-53	12
4 <sup>16</sup>	Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. <b>2011</b> , 28 Suppl 1, S253-8	14
4 <sup>15</sup>	Treatment recommendations for metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2011</b> , 13, 162-78	3.6 21
4 <sup>14</sup>	Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. <b>2011</b> , 32, 417-24	12
4 <sup>13</sup>	Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. <b>2011</b> , 6, 133-45	40
4 <sup>12</sup>	Future Solutions for Patients with Metastatic Colorectal Cancer Positive for K-RAS Mutations. <b>2011</b> , 7, 275-280	
4 <sup>11</sup>	The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. <b>2011</b> , 12, 144	33
4 <sup>10</sup>	EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. <b>2011</b> , 11, 107	15
4 <sup>09</sup>	Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. <b>2011</b> , 11, 496	39
4 <sup>08</sup>	The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. <b>2011</b> , 104, 661-6	12
4 <sup>07</sup>	The inhibitory effects of 5-hydroxy-3,6,7,8,3',4'-hexamethoxyflavone on human colon cancer cells. <b>2011</b> , 55, 1523-32	28
4 <sup>06</sup>	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. <b>2011</b> , 50, 307-12	274
4 <sup>05</sup>	Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review. <b>2011</b> , 39, 703-10	46
4 <sup>04</sup>	XELOX in colorectal cancer: a convenient option for the future?. <b>2011</b> , 5, 9-19	4
4 <sup>03</sup>	Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?. <b>2011</b> , 8, 175-182	9
4 <sup>02</sup>	Changing pathology with changing drugs: tumors of the gastrointestinal tract. <b>2011</b> , 78, 76-89	13
4 <sup>01</sup>	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. <b>2011</b> , 11, 777-92	170

400	Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2011</b> , 135, 1278-82	5	17
399	Genomics, health care, and society. <b>2011</b> , 365, 1033-41		110
398	Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. <b>2011</b> , 29, 3419-26		299
397	Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. <b>2011</b> , 16, 1557-64		64
396	HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. <b>2011</b> , 17, 472-82		147
395	Kinase suppressor of ras 1 (KSR1) regulates PGC1 $\alpha$ and estrogen-related receptor $\alpha$ to promote oncogenic Ras-dependent anchorage-independent growth. <b>2011</b> , 31, 2453-61		32
394	Review of histopathological and molecular prognostic features in colorectal cancer. <i>Cancers</i> , <b>2011</b> , 3, 2767-810	6.6	51
393	Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. <b>2011</b> , 16, 1006-20		12
392	Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1127-1132	10.3	73
391	Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients. <b>2011</b> , 81, 359-64		10
390	Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. <b>2011</b> , 17, 2744-56		60
389	Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. <b>2011</b> , 105, 246-54		23
388	Prognostic value of colorectal cancer biomarkers. <i>Cancers</i> , <b>2011</b> , 3, 2080-105	6.6	3
387	MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. <b>2011</b> , 71, 445-53		73
386	KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. <b>2011</b> , 17, 6338-46		54
385	Pharmacogenetics and pharmacogenomics: a clinical reality. <b>2011</b> , 48, 410-7		15
384	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. <i>Cancers</i> , <b>2011</b> , 3, 2014-31	6.6	23
383	KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues. <b>2011</b> , 12, 3191-204		48

382	Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. <b>2011</b> , 17, 6329-37		77
381	KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. <b>2012</b> , 25, 731-9		27
380	Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2012</b> , 136, 1298-307	5	18
379	KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13. <b>2012</b> , 21, 14-23		13
378	Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. <b>2012</b> , 24, 297-304		15
377	Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer. <b>2012</b> , 82, 83-9		18
376	Personalized medicine in colorectal cancer: the evidence so far. <b>2012</b> , 2, 1013-1021		
375	Validation of KRAS testing for anti-EGFR therapeutic decisions for patients with metastatic colorectal carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2012</b> , 136, 26-32	5	24
374	KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. <b>2012</b> , 107, 340-4		24
373	Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. <b>2012</b> , 30, 4566-72		163
372	The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. <i>Annals of Oncology</i> , <b>2012</b> , 23, 948-54	10.3	78
371	Long-term treatment of metastatic colorectal cancer with panitumumab. <b>2012</b> , 6, 125-35		2
370	Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. <b>2012</b> , 2012, 387172		11
369	Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?. <b>2012</b> , 2012, 838509		1
368	Pharmacogenetic screening for drug therapy: from single gene markers to decision making in the next generation sequencing era. <b>2012</b> , 44, 166-80		17
367	The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. <b>2012</b> , 61, 1117-24		20
366	The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. <b>2012</b> , 17, 1225-39		352
365	Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. <b>2012</b> , 11, 291-6		29

364	Genetic and epigenetic biomarkers of colorectal cancer. <b>2012</b> , 10, 9-15		31
363	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2313-2318	10.3	129
362	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1518-25	10.3	135
361	When progressive disease does not mean treatment failure: reconsidering the criteria for progression. <b>2012</b> , 104, 1534-41		96
360	Reovirus: a targeted therapeutic--progress and potential. <b>2012</b> , 10, 1514-25		49
359	PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. <b>2012</b> , 11, 143-50		80
358	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. <b>2012</b> , 48, 1466-75		432
357	Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. <b>2012</b> , 13, 663-75		17
356	Paying for personalized care: cancer biomarkers and comparative effectiveness. <b>2012</b> , 6, 260-6		17
355	Introduction: personalized medicine in gastrointestinal cancer. <b>2012</b> , 16, 1639-40		1
354	Study of KRAS new predictive marker in a clinical laboratory. <i>Clinical and Translational Oncology</i> , <b>2012</b> , 14, 937-42	3.6	3
353	Prognostic and predictive roles of KRAS mutation in colorectal cancer. <b>2012</b> , 13, 12153-68		135
352	Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. <b>2013</b> , 18, 1519-26		24
351	Cetuximab and biomarkers in non-small-cell lung carcinoma. <b>2012</b> , 6, 221-31		8
350	Cetuximab in metastatic colorectal cancer. <b>2012</b> , 12, 555-65		27
349	Cancer Biomarkers for Diagnosis, Prognosis and Therapy. <b>2012</b> , 18-68		1
348	Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany. <b>2012</b> , 131, 438-45		53
347	KRAS und weitere Signalmoleküle für die Therapieentscheidung beim metastasierten Kolonkarzinom. <b>2012</b> , 7, 24-29		1

346	Loss of PTEN expression as a predictor of resistance to anti-EGFR monoclonal therapy in metastatic colorectal cancer: evidence from retrospective studies. <b>2012</b> , 69, 1647-55	27
345	Involvement of store-operated calcium signaling in EGF-mediated COX-2 gene activation in cancer cells. <b>2012</b> , 24, 162-9	58
344	MicroRNA profiling differentiates colorectal cancer according to KRAS status. <b>2012</b> , 51, 1-9	89
343	CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material. <b>2012</b> , 51, 344-52	30
342	PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. <b>2012</b> , 227, 927-33	5
341	Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer. <b>2012</b> , 8, 42-50	4
340	Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <b>2012</b> , 30, 787-93	13
339	First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. <b>2012</b> , 138, 65-72	68
338	Biologie moléculaire et prise en charge des cancers colorectaux. <b>2012</b> , 14, 45-51	
337	Fool's gold, lost treasures, and the randomized clinical trial. <b>2013</b> , 13, 193	36
336	High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. <b>2013</b> , 13, 169	36
335	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. <b>2013</b> , 13, 49	84
334	Pharmacophore modeling, 3D-QSAR, and molecular docking study on naphthyridine derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1. <b>2013</b> , 22, 3812-3822	2
333	Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: the morphologic response criteria. <b>2013</b> , 9, 198-202	16
332	The usability of allele-specific PCR and reverse-hybridization assays for KRAS genotyping in Serbian colorectal cancer patients. <b>2013</b> , 58, 998-1003	7
331	An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. <b>2013</b> , 8, 127-36	25
330	Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. <b>2013</b> , 72, 223-30	27
329	Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?. <b>2013</b> , 2, 185	1

328	Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. <b>2013</b> , 30, 329-61	10
327	Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. <b>2013</b> , 180, 97-103	40
326	Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. <b>2013</b> , 61, 273-6	11
325	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1267-73	10.3 79
324	Circulating tumor cells in colorectal cancer patients. <b>2013</b> , 39, 759-72	40
323	Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study. <b>2013</b> , 4, 17	26
322	Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. <b>2013</b> , 20, 2166-71	64
321	Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review. <b>2013</b> , 31, 215-28	23
320	Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. <b>2013</b> , 32, 92	66
319	PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis. <b>2013</b> , 139, 891-900	25
318	Selection for hepatic resection of colorectal liver metastases: expert consensus statement. <b>2013</b> , 15, 91-103	214
317	Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. <b>2013</b> , 12, 45-53	12
316	Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer. <b>2013</b> , 16, 288-96	29
315	Comparison of KRAS genotype: the rascreen assay vs. LNA-mediated qPCR clamping assay. <b>2013</b> , 12, 195-203.e2	
314	KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. <b>2013</b> , 22, 105-11	45
313	Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy. <b>2013</b> , 30, 415	6
312	Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas. <b>2013</b> , 462, 329-35	29
311	Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. <b>2013</b> , 18, 670-7	23

310	Management of advanced colorectal cancer, Part 2. <b>2013</b> , 70, 491-506		16
309	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. <b>2013</b> , 62, 540-9		107
308	Individualized therapy for metastatic colorectal cancer. <b>2013</b> , 274, 1-24		19
307	A colorectal cancer classification system that associates cellular phenotype and responses to therapy. <b>2013</b> , 19, 619-25		670
306	Predictive and Prognostic Biomarkers for Colorectal Cancer. <b>2013</b> , 131-162		2
305	Role of targeted agents in metastatic colorectal cancer. <b>2013</b> , 8, 83-96		52
304	Sporadische Tumoren des Kolorektums. <b>2013</b> , 611-661		
303	Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. <b>2013</b> , 85, 45-81		78
302	Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. <b>2013</b> , 12, 343-55		355
301	Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. <b>2013</b> , 11, 115-129		2
300	Tumour heterogeneity in the clinic. <b>2013</b> , 501, 355-64		770
299	Rolle und Aufgaben der chirurgischen Onkologie im Rahmen molekular definierter Therapien. <b>2013</b> , 19, 858-862		
298	KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. <b>2013</b> , 119, 714-21		72
297	DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. <b>2013</b> , 18, 516-24		17
296	RASmutations: impact on treatment outcome. <b>2013</b> , 2, 525-534		
295	A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. <i>Current Oncology</i> , <b>2013</b> , 20, e107-12	2.8	2
294	Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2013</b> , 137, 820-7	5	26
293	Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. <b>2013</b> , 42, 411-21		33

292	Response phenotype as a predictive biomarker to guide treatment with targeted therapies. <b>2013</b> , 31, 3739-41		4
291	FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1769-1777	10.3	37
290	Biomarkers in precision therapy in colorectal cancer. <b>2013</b> , 1, 166-83		69
289	Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. <b>2013</b> , 8, e55793		48
288	Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. <b>2013</b> , 31, 3764-75		155
287	Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer. <b>2013</b> , 2, 11-20		16
286	Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer. <b>2013</b> , 2, 205-12		2
285	Colorectal cancer. <b>2013</b> , 10-26		
284	Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. <b>2013</b> , 18, 850-64		70
283	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. <b>2013</b> , 183-232		
282	Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer. <b>2013</b> , 5, 1295-1300		7
281	Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. <b>2013</b> , 5, 1741-1743		9
280	Comparison of KRAS/BRAF mutations between primary tumors and serum in colorectal cancer: Biological and clinical implications. <b>2013</b> , 5, 249-254		10
279	Personalized treatment for advanced colorectal cancer: KRAS and beyond. <i>Cancer Management and Research</i> , <b>2013</b> , 5, 387-400	3.6	15
278	Cetuximab related eyelash elongations for patients with metastatic rectum carcinoma: metabolic complete response. <b>2013</b> , 25, 504-5		
277	Strategic Issues in the Adoption of Genome-Based Diagnostics. <b>2013</b> , 447-456		2
276	TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells. <b>2013</b> , 8, e70604		21
275	Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells. <b>2013</b> , 8, e66302		20

274	PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis. <b>2014</b> , 9, e107926		6
273	Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. <b>2014</b> , 10, 1-9		26
272	Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. <b>2014</b> , 18, 7-16		9
271	Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 943-56	5.6	165
270	Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity. <b>2014</b> , 15, 623-32		25
269	Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives. <b>2014</b> , 10, 380-394		1
268	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. <b>2014</b> , 15, 1701-15		4
267	Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. <b>2014</b> , 13, 353-7		60
266	KRAS and BRAF mutational status in colon cancer from Albanian patients. <b>2014</b> , 9, 187		11
265	Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3. <b>2014</b> , 7, 103		4
264	Molecular Predictive and Prognostic Markers of Colorectal Carcinoma. <b>2014</b> , 19, 252-255		
263	Variability in assessing treatment response: metastatic colorectal cancer as a paradigm. <b>2014</b> , 20, 3560-8		14
262	Molecular Pathology and Diagnostics of Colorectal Cancer. <b>2014</b> , 119-175		
261	Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. <i>BioMed Research International</i> , <b>2014</b> , 2014, 591867	3	9
260	Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). <b>2014</b> , 87, 7-20		67
259	Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasisPeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 7 February 2014View all notes. <b>2014</b> , 50, 203-209		11
258	Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique. <b>2014</b> , 16, 120-128		3
257	Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. <b>2014</b> , 21 Suppl 3, S390-7		58

256	High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles. <b>2014</b> , 406, 2477-87		14
255	KRAS mutations: analytical considerations. <b>2014</b> , 431, 211-20		24
254	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1346-1355	10.3	353
253	Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. <b>2014</b> , 20, 265-272		27
252	Clinical relevance of KRAS mutations in codon 13: Where are we?. <b>2014</b> , 343, 1-5		21
251	Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 107-16	10.3	137
250	Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip. <b>2014</b> , 35, 9639-47		1
249	Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer. <b>2014</b> , 10, 263-271		1
248	Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. <b>2014</b> , 20, 6346-56		21
247	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. <b>2014</b> , 50, 3136-44		15
246	A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. <b>2014</b> , 20, 4499-4510 <sup>44</sup>		
245	Risk factors for stent-related adverse events in patients with obstructive colorectal cancer: are we missing something?. <b>2014</b> , 80, 742-743		1
244	Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. <b>2014</b> , 67, 764-7		23
243	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <b>2014</b> , 15, 862-73		190
242	Somatic alterations as the basis for resistance to targeted therapies. <b>2014</b> , 232, 244-54		27
241	Cetuximab (Erbix). <b>2014</b> , 1501-1520		
240	Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories. <b>2014</b> , 74, 1-13		15
239	Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan. <b>2014</b> , 44, 1457-64		4

238	Highly sensitive KRAS mutation detection from formalin-fixed paraffin-embedded biopsies and circulating tumour cells using wild-type blocking polymerase chain reaction and Sanger sequencing. <i>Molecular Diagnosis and Therapy</i> , <b>2014</b> , 18, 459-68	4.5	3
237	A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report. <b>2014</b> , 12, 63		
236	Detection of activated KRAS from cancer patient peripheral blood using a weighted enzymatic chip array. <b>2014</b> , 12, 147		6
235	Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer. <b>2014</b> , 45, 366-74		7
234	Influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study. <b>2014</b> , 46, 561-7		11
233	Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay. <b>2014</b> , 436, 169-75		8
232	Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 9732-43	5.6	25
231	siRNA blocking the RAS signalling pathway and inhibits the growth of oesophageal squamous cell carcinoma in nude mice. <b>2014</b> , 32, 625-9		1
230	Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer. <b>2014</b> , 31, 2115-22		34
229	Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. <b>2015</b> , 94, e1698		5
228	Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases. <b>2015</b> , 5, 18678		74
227	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <b>2015</b> , 15, 747		6
226	KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery. <b>2015</b> , 94, e1284		10
225	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. <b>2015</b> , 6, 28716-30		9
224	Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 3185-92	4.4	4
223	Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. <b>2015</b> , 10, e0131091		8
222	Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. <b>2015</b> , 10, e0140717		9
221	Colorectal Cancer Biomarkers: Where Are We Now?. <i>BioMed Research International</i> , <b>2015</b> , 2015, 149014 3		111

220	Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. <i>World Journal of Gastrointestinal Oncology</i> , <b>2015</b> , 7, 47-54	3.4	14
219	Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. <b>2015</b> , 6, 133-41		59
218	Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. <b>2015</b> , 3, 179-184		16
217	Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. <b>2015</b> , 22, 2640-8		49
216	KRAS mutation testing in clinical practice. <b>2015</b> , 15, 375-84		9
215	KRAS mutation screening by chip-based DNA hybridization--a further step towards personalized oncology. <b>2015</b> , 140, 2747-54		4
214	Hyperplastic polyps of the colon and rectum - reclassification, BRAF and KRAS status in index polyps and subsequent colorectal carcinoma. <b>2015</b> , 123, 298-304		8
213	Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations. <b>2015</b> , 15, 715-25		5
212	EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selection. <b>2015</b> , 154, 67-77		35
211	Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. <b>2015</b> , 113, 37-45		41
210	RAS status in Korean patients with stage III and IV colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2015</b> , 17, 751-6	3.6	5
209	Pharmacologic treatment options for advanced epithelial skin cancer. <b>2015</b> , 16, 1479-93		17
208	Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. <b>2015</b> , 113, 680-5		10
207	Second-line outcomes in metastatic colorectal cancer--raising the bar for the high jump rather than the doing the limbo. <b>2015</b> , 15, 133-43		2
206	Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. <b>2015</b> , 48, 908-10		23
205	Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors. <b>2015</b> , 211, 349-55		25
204	Viable pigs with a conditionally-activated oncogenic KRAS mutation. <b>2015</b> , 24, 509-17		24
203	Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. <b>2015</b> , 4, 7		7

202	Application of biomarkers in oncology clinical trials. <b>2015</b> , 5, 61-74		1
201	Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value. <b>2015</b> , 44, 484-92		18
200	Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. <b>2015</b> , 26, 371-8		8
199	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. <b>2015</b> , 15, 530		15
198	Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. <b>2015</b> , 16, 41		6
197	Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. <b>2015</b> , 75, 1739-56		6
196	KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?. <b>2015</b> , 113, 914-20		7
195	Defining an optimal surgical strategy for synchronous colorectal liver metastases: staged versus simultaneous resection?. <b>2015</b> , 85, 829-33		13
194	Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. <b>2015</b> , 112, 313-8		21
193	A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. <b>2015</b> , 33, 138-47		16
192	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <b>2015</b> , 33, 22-8		69
191	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. <b>2015</b> , 21, 1087-97		122
190	Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options. <i>BioMed Research International</i> , <b>2016</b> , 2016, 6896024	3	17
189	Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer. <b>2016</b> , 11, e0157830		51
188	Colonic Polyps and Colorectal Cancer. <b>2016</b> , 349-356		
187	The Economics of Personalized Therapy in Metastatic Colorectal Cancer. <b>2016</b> , 12, 123-129		1
186	Colorectal Cancer. <b>2016</b> , 28, 71-72		1
185	KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer. <b>2016</b> , 5, e253		18

184	Cost-effectiveness of cetuximab for colorectal cancer. <b>2016</b> , 16, 667-677	8
183	A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing. <b>2016</b> , 16, 585	7
182	BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer. <b>2016</b> , 5, 95-108	4
181	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <b>2016</b> , 16, 339	11
180	Mutation spectra of RAS gene family in colorectal cancer. <b>2016</b> , 212, 537-544.e3	31
179	A comparison of four methods for detecting mutations in formalin-fixed specimens from metastatic colorectal cancer patients. <b>2016</b> , 12, 150-156	9
178	Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. <b>2016</b> , 78, 397-403	5
177	Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer. <b>2016</b> , 114, 372-80	22
176	Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. <b>2016</b> , 389, 263-73	23
175	A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. <b>2016</b> , 139, 177-86	40
174	Quality assurance in clinical trials--the role of pathology. <b>2016</b> , 468, 83-92	7
173	Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value. <b>2016</b> , 50, 90-100	16
172	Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras. <b>2016</b> , 51, 447-57	6
171	Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers. <i>Technology in Cancer Research and Treatment</i> , <b>2016</b> , 15, 573-82	2.7 6
170	Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab. <b>2016</b> , 7, 11-7	4
169	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <b>2017</b> , 53, 79-97	64
168	Serum and tissue markers in colorectal cancer: State of art. <b>2017</b> , 111, 103-116	19
167	Molecular classification of gastric cancer. <b>2017</b> , 17, 293-301	47

166	Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement. <b>2017</b> , 25, 356-367	8
165	Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis. <b>2017</b> , 96, e6335	5
164	Sulfatase-2 promotes the growth and metastasis of colorectal cancer by activating Akt and Erk1/2 pathways. <b>2017</b> , 89, 1370-1377	15
163	Molekulare Testungen bei onkologischen Erkrankungen. <b>2017</b> , 20, 39-45	
162	Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. <b>2017</b> , 15, 220-235	54
161	biomarker testing disparities in colorectal cancer patients in New Mexico. <b>2017</b> , 3, e00448	6
160	Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. <b>2017</b> , 213, 377-387	34
159	Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. <b>2017</b> , 64, 107-115	45
158	Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis. <b>2017</b> , 32, e421-e427	10
157	Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size. <b>2017</b> , 2, e000275	6
156	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. <i>Cancers</i> , <b>2017</b> , 9,	6.6 628
155	Regulatory miRNAs in Colorectal Carcinogenesis and Metastasis. <b>2017</b> , 18,	26
154	Survival prediction in patients with resectable colorectal liver metastases: Clinical risk scores and tumor response to chemotherapy. <b>2017</b> , 14, 8051-8059	9
153	EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics. <b>2017</b> , 8, 17810-17818	18
152	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence hybridization (FISH) to select the optimal patients for matched therapy?. <b>2017</b> , 8, 100863-100898	11
151	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. <b>2018</b> , 17, 1595-1601	18
150	LncRNA HIF1A-AS2 positively affects the progression and EMT formation of colorectal cancer through regulating miR-129-5p and DNMT3A. <b>2018</b> , 98, 433-439	63
149	Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration. <b>2018</b> , 2,	4

148	Serum level of octanoic acid predicts the efficacy of chemotherapy for colorectal cancer. <b>2019</b> , 17, 831-842	7
147	Acquired and Intrinsic Resistance to Colorectal Cancer Treatment. <b>2018</b> ,	3
146	EPA significantly improves anti-EGFR targeted therapy by regulating miR-378 expression in colorectal cancer. <b>2018</b> , 16, 6188-6194	5
145	Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment. <b>2019</b> , 9, 11346	7
144	Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials. <b>2019</b> , 24, 1397-1405	
143	Colorectal cancer in adolescents and young adults: Defining a growing threat. <b>2019</b> , 66, e27941	19
142	CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. <b>2019</b> , 118, 38-43	21
141	A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations. <b>2019</b> , 18, 600-626	5
140	Precision medicine for metastatic colorectal cancer: an evolving era. <b>2019</b> , 13, 919-931	21
139	Systemic Therapy for Advanced and Metastatic Colon Cancer. <b>2019</b> , 73, 202	
138	Sensitive and selective detections of codon 12 and 13 KRAS mutations in a single tube using modified wild-type blocker. <b>2019</b> , 494, 123-131	1
137	Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma. <b>2019</b> , 34, 288-296	5
136	Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. <b>2019</b> , 286, 1305-1318	18
135	The Translational Status of Cancer Liquid Biopsies. <b>2019</b> , 7, 312	16
134	Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting. <b>2019</b> , 12, 502-512	9
133	Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?. <b>2020</b> , 26, 781-786	
132	The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer. <b>2020</b> , 59, 152-159	8
131	Designing clinical studies for biomarker discovery: The Design criteria. <b>2020</b> , 441-466	

130	ZEB2-AS1 Accelerates Epithelial/Mesenchymal Transition Through miR-1205/CRKL Pathway in Colorectal Cancer. <b>2020</b> , 35, 153-162	8
129	Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 8527-8534	1
128	KRAS: From undruggable to a druggable Cancer Target. <b>2020</b> , 89, 102070	51
127	and mutations in metastatic colorectal cancer: future perspectives for personalized therapy. <b>2020</b> , 8, 192-205	18
126	TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer. <b>2020</b> , 10, 13896	3
125	Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients. <b>2020</b> , 9, CRC14	2
124	Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab. <b>2020</b> , 20, 416	3
123	The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. <b>2020</b> , 99, e19210	1
122	Predictive biomarkers of drug resistance in colorectal cancerRecent updates. <b>2020</b> , 135-151	1
121	Effectiveness of <i>Vigna unguiculata</i> seed extracts in preventing colorectal cancer. <b>2020</b> , 11, 5853-5865	3
120	Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants. <b>2020</b> , 6, 111-129	6
119	Latency and interval therapy affect the evolution in metastatic colorectal cancer. <b>2020</b> , 10, 581	4
118	The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection. <b>2020</b> , 62, 1476-1493	2
117	Realizing Cancer Precision Medicine by Integrating Systems Biology and Nanomaterial Engineering. <b>2020</b> , 32, e1906783	11
116	Proteomic profiling reveals a signature for optimizing prognostic prediction in Colon Cancer. <b>2021</b> , 12, 2199-2205	0
115	Mechanisms of Cetuximab Resistance and How to Overcome It. <b>2021</b> , 21-51	
114	Imaging features associated with survival outcomes among colorectal cancer patients with and without KRAS mutation. <b>2021</b> , 52,	1
113	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <b>2021</b> , 19, 329-359	153

112	Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. <b>2021</b> , 17, 1483-1494	4
111	Comprehensive Clinical and Molecular Characterization of -Mutant Colorectal Cancer. <b>2021</b> , 5,	7
110	Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. <b>2021</b> , 11, 7402	0
109	Prevalence of colorectal cancer biomarkers and their impact on clinical outcomes in Riyadh, Saudi Arabia. <b>2021</b> , 16, e0249590	2
108	Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer. <b>2021</b> ,	0
107	Treatment sequencing of metastatic colorectal cancer based on primary tumor location. <b>2021</b> , 48, 119-129	0
106	Comparison of Methods for Analyzing Radiological Response of Colorectal Cancer Liver Metastasis After Neoadjuvant Chemotherapeutic Treatment. <b>2021</b> , 18,	
105	Colon and Rectum. <b>2010</b> , 143-164	35
104	Colon and Rectum. <b>2010</b> , 173-206	5
103	Targeting Heat Shock Proteins in Colorectal Cancer. <b>2015</b> , 345-379	2
102	Stratifying Cancer Therapies by Molecular Interactions and Imaging. <b>2017</b> , 315-358	1
101	Identification of Biomarkers for Pharmacological Activity. <b>2013</b> , 189-205	1
100	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. <b>2011</b> , 121, 4311-21	159
99	PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. <b>2015</b> , 125, 4529-43	85
98	Cancer genome landscape: a radiologist's guide to cancer genome medicine with imaging correlates. <b>2019</b> , 10, 111	2
97	KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. <b>2010</b> , 2,	6
96	A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer. <b>2015</b> , 10, e0140187	5
95	A Systematic Literature Review and Meta-Analysis Describing the Prevalence of , and Gene Mutations in Metastatic Colorectal Cancer. <b>2020</b> , 13, 184-198	5

94	[The RAS paradox of the EGFR-targeted therapy in colorectal cancer]. <b>2008</b> , 52, 185-91		2
93	Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma. <b>2014</b> , 1, 40-45		10
92	LncRNA CHR1-induced miR-489 loss promotes metastasis of colorectal cancer via TWIST1/EMT signaling pathway. <b>2017</b> , 8, 36410-36422		54
91	Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. <b>2019</b> , 10, 5510-5522		4
90	Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. <b>2015</b> , 6, 16059-68		50
89	<sup>89</sup> Zr-cetuximab PET imaging in patients with advanced colorectal cancer. <b>2015</b> , 6, 30384-93		82
88	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. <b>2016</b> , 7, 24088-96		9
87	First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab. <i>OncoTargets and Therapy</i> , <b>2009</b> , 2, 73-82	4.4	3
86	Coexistence of and Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. <i>Cell Journal</i> , <b>2017</b> , 19, 113-117	2.4	29
85	The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. <i>Deutsches A&amp;#x0308;rztblatt International</i> , <b>2009</b> , 106, 202-6	2.5	15
84	Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer. <i>Current Oncology</i> , <b>2010</b> , 17 Suppl 1, S3-17	2.8	44
83	Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 1177-87	5.6	18
82	Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 3133-43	5.6	92
81	Role of surgery in colorectal liver metastases: too early or too late?. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 3484-90	5.6	13
80	KRAS mutation testing in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 5171-80	5.80	129
79	Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3858-74	5.6	39
78	Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 6102-12	5.6	44
77	Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 6944-54	5.6	47

76	Markers of resistance to anti-EGFR therapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2013</b> , 4, 308-18	2.8	35
75	Cost-effectiveness Analysis of Cetuximab in Treatment of Metastatic Colorectal Cancer in Iranian Pharmaceutical Market. <i>International Journal of Preventive Medicine</i> , <b>2015</b> , 6, 63	1.6	8
74	Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples. <i>Clinical Medicine Insights Pathology</i> , <b>2012</b> , 5, 15-22		39
73	EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from ERBITUX-OUEST <i>Open Journal of Internal Medicine</i> , <b>2016</b> , 06, 56-67	0.2	1
72	Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus. <i>Turkish Journal of Gastroenterology</i> , <b>2020</b> , 31, 695-705	1	1
71	Molecular Markers in Sex Differences in Cancer. <i>Toxicological Research</i> , <b>2019</b> , 35, 331-341	3.7	15
70	The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2009</b> , 133, 1600-6	5	92
69	Practical and molecular evaluation of colorectal cancer: new roles for the pathologist in the era of targeted therapy. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2010</b> , 134, 853-63	5	12
68	Molecular diagnostics of colorectal cancer. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2011</b> , 135, 578-87	5	41
67	Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. <i>Molecular Cancer</i> , <b>2021</b> , 20, 128	42.1	10
66	Pré-requis avant la mise en route d'une chimiothérapie pour cancer colorectal. <b>2009</b> , 30-46		
65	Progress in the treatment of colorectal cancer: the impact of new drugs. <b>2009</b> , 176-190		
64	Advances in the Treatment of Colorectal Cancer: Targeting Receptors of Disease. <b>2009</b> , 523-532		
63	Unusual pancreatic tumours. <b>2009</b> , 195-206		
62	Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies. <b>2009</b> , 321-363		
61	Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. <i>OncoTargets and Therapy</i> , <b>2009</b> , 2, 161-70	4.4	2
60	Inherent Resistance to Epidermal Growth Factor Receptor Antibodies in Refractory Metastatic Colorectal Cancer. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , <b>2009</b> , 9, 165-174	0.5	1
59	EGFR-Directed Monoclonal Antibodies. <b>2010</b> , 407-436		

58	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. <b>2009</b> , 3, 48-53		
57	Pharmacogenetics in Colorectal Cancer. <b>2010</b> , 61-86		
56	Which therapy for which patient?. <b>2011</b> , 56-72		
55	Clinical results with EGFR inhibitors in colorectal cancer. <b>2012</b> , 44-59		
54	Survival Outcome in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Followed by Cetuximab. <i>International Journal of Clinical Medicine</i> , <b>2012</b> , 03, 263-269	0.3	
53	Molecular Mechanisms and Pathology of Gastric Carcinogenesis: Sporadic Cancers. <i>Molecular Pathology Library</i> , <b>2013</b> , 67-81		
52	Les anti-EGFR personnalisés selon le statut tumoral KRAS. <b>2013</b> , 159-175		
51	Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. <b>2014</b> , 343-359		
50	EGF/EGFR signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells. <i>ScienceOpen Research</i> ,		1
49	Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers. <i>South Asian Journal of Cancer</i> , <b>2014</b> , 3, 175-8	0.7	1
48	Epidermal growth factor/epidermal growth factor receptor signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells. <i>ScienceOpen Research</i> ,		
47	Next-Generation Sequencing Applications in Head and Neck Oncology. <b>2015</b> , 401-422		
46	A Mathematical Model for Assessing KRAS Mutation Effect on Monoclonal Antibody Treatment of Colorectal Cancer. <i>Lecture Notes in Computer Science</i> , <b>2015</b> , 243-258	0.9	2
45	Colorectal and Anal Tumors. <i>Pediatric Oncology</i> , <b>2017</b> , 319-333	0.5	
44	Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study. <i>Middle East Journal of Digestive Diseases</i> , <b>2018</b> , 10, 18-23	1.1	
43	Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation. <i>Meditsinskiy Sovet</i> , <b>2018</b> , 32-41	0.4	1
42	KRAS as Potential Target in Colorectal Cancer Therapy. <b>2019</b> , 389-424		0
41	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4

40	Identification of Key Genes and Prognostic Analysis between Chromophobe Renal Cell Carcinoma and Renal Oncocytoma by Bioinformatic Analysis. <i>BioMed Research International</i> , <b>2020</b> , 2020, 4030915	3	3
39	Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2009</b> , 3, 171-2		2
38	Pharmacogenetics: implementing personalized medicine. <i>Clinical Cases in Mineral and Bone Metabolism</i> , <b>2009</b> , 6, 17-24		28
37	Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2009</b> , 3, S73-8		2
36	Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2009</b> , 3, S23-7		2
35	The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist. <i>P and T</i> , <b>2010</b> , 35, 219-29	1.4	1
34	Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. <i>OncoTargets and Therapy</i> , <b>2009</b> , 2, 17-27	4.4	3
33	Evolving role of cetuximab in the treatment of colorectal cancer. <i>Cancer Management and Research</i> , <b>2009</b> , 1, 79-88	3.6	3
32	Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. <i>American Journal of Cancer Research</i> , <b>2011</b> , 1, 650-62	4.4	22
31	Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2011</b> , 4, 168-72		12
30	Alternate dosing of cetuximab for patients with metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2013</b> , 6, 47-55		7
29	The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2015</b> , 8, 334-45		8
28	Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. <i>Cancer Biology and Medicine</i> , <b>2016</b> , 13, 136-41	5.2	1
27	Forward selection two sample binomial test. <i>Journal of Data Science</i> , <b>2014</b> , 12, 279-294	2.1	1
26	A novel E1B55kDa-deleted oncolytic adenovirus carrying microRNA-143 exerts specific antitumor efficacy on colorectal cancer cells. <i>American Journal of Translational Research (discontinued)</i> , <b>2016</b> , 8, 3822-3830	3	7
25	Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. <b>2017</b> , 3, 105-111		40
24	KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. <i>Caspian Journal of Internal Medicine</i> , <b>2020</b> , 11, 355-369	1	
23	Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. <i>Technology in Cancer Research and Treatment</i> , <b>2021</b> , 20, 15330338211039131	2.7	

22	Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. <i>Technology in Cancer Research and Treatment</i> , <b>2021</b> , 20, 153303382110391	2.7	
21	Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. <i>Molecular Diagnosis and Therapy</i> , <b>2021</b> , 25, 715-734	4.5	1
20	Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling.. <i>Biomedicines</i> , <b>2022</b> , 10,	4.8	0
19	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , <b>2009</b> , 11, 737-47	3.6	3
18	First passage time analysis of spatial mutation patterns reveals evolutionary dynamics of pre-existing resistance in colorectal cancer.		
17	A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.. <i>Langenbeck's Archives of Surgery</i> , <b>2022</b> , 1	3.4	1
16	Colorectal cancer carcinogenesis: From bench to bedside.. <i>World Journal of Gastrointestinal Oncology</i> , <b>2022</b> , 14, 654-663	3.4	1
15	Medicina de precisión en cáncer colorrectal y gastroesofágico avanzado. <i>Revista Médica Clínica Las Condes</i> , <b>2022</b> , 33, 125-139	0.2	
14	Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer. <i>Current Issues in Molecular Biology</i> , <b>2022</b> , 44, 1552-1563	2.9	0
13	Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.. <i>Journal of Medical Economics</i> , <b>2022</b> , 1-25	2.4	1
12	Deep learning with whole slide images can improve the prognostic risk stratification with stage III colorectal cancer. <i>Computer Methods and Programs in Biomedicine</i> , <b>2022</b> , 221, 106914	6.9	1
11	Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal		0
10	Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.		
9	Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. <b>2022</b> , 14, 175883592211117		0
8	Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. <b>2022</b> , 14, 4834		0
7	Cetuximab severe cutaneous toxicity as a gateway for bacteremia: case report. <b>2023</b> , 34, 187-189		0
6	Current Targeted Therapy for Metastatic Colorectal Cancer. <b>2023</b> , 24, 1702		1
5	Targeting ERBB2 overcomes resistance to the anti-EGFR therapeutic antibody cetuximab. <b>2023</b> , 75-81		0

- 4 Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. **2023**, 13-27
- 3 Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. **2023**, 15, 1679
- 2 First passage time analysis of spatial mutation patterns reveals sub-clonal evolutionary dynamics in colorectal cancer. **2023**, 19, e1010952
- 1 Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. 29, 1911-1941